Clinical Trial Update: Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating lenalidomide combined with azacitidine in intermediate-2 or high-risk myelodysplastic syndromes with deletion 5q; study status complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Groupe Francophone des Myelodysplasies | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED